33 Its safety and efficacy have been evaluated in five randomized clinical trials in a total of 1,710 patients.29,34–36 The ASCEND trial, in which 555 patients with IPF were randomized to receive either the maximum oral dose of pirfenidone (2,403 mg/d) or placebo, confirmed that ...
Nintedanib (BIBF1120) is an oral small-molecule inhibitor of receptor tyrosine kinases including fibroblast growth factor receptor (FGFR) 1 to 3, platelet-derived growth factor receptor (PDGFR) α and β, and VEGF receptor (VEGFR) 1 to 3 and has been approved for the treatment of lung adenoc...
Sorafenib in combination with Capecitabine: an Oral regimen for patients with HER2-negative locally advanced or metastatic breast Cancer. J Clin Oncol. 2012;30:1484–91. Article CAS PubMed Google Scholar du Bois A, Huober J, Stopfer P, Pfisterer J, Wimberger P, Loibl S, et al. A ...
Sorafenib in combination with Capecitabine: an Oral regimen for patients with HER2-negative locally advanced or metastatic breast Cancer. J Clin Oncol. 2012;30:1484–91. Article CAS PubMed Google Scholar du Bois A, Huober J, Stopfer P, Pfisterer J, Wimberger P, Loibl S, et al. A ...